$0.31
+0.02 (+6.55%)
Open$0.30
Previous Close$0.29
Day High$0.33
Day Low$0.30
52W High$20.29
52W Low$7.67
Volume—
Avg Volume259.9K
Market Cap4.07M
P/E Ratio40.64
EPS$0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+6,401.0% upside
Current
$0.31
$0.31
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 642.8K | 653.1K | 554.3K |
| Net Income | 87.6K | 116.0K | 91.5K |
| Profit Margin | 13.6% | 17.8% | 16.5% |
| EBITDA | 188.3K | 172.6K | 151.1K |
| Free Cash Flow | 84.6K | 101.3K | 71.5K |
| Rev Growth | +14.5% | -9.1% | -7.1% |
| Debt/Equity | 0.32 | 0.30 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |